En vivo
LabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech mediaLonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma PostEli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSNThermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo FinanceBio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.comEli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - StocktwitsPfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord PharmaEndpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for VoyxactAgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.stBoston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDeviceCharles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWS
Cell 11 mar 2026

Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility

Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility

Original
Contenido no disponible. Consulta la fuente original.